A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
For more information about the trial above please contact the study team:
Principal Investigator, Anand Sharma, at firstname.lastname@example.org.
Study Coordinator, Nikki Hill, at email@example.com.
Trial opened at the following institutions: Medical University of South Carolina